Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.82 - $18.01 $67,962 - $253,941
-14,100 Reduced 26.06%
40,000 $15 Million
Q1 2024

May 13, 2024

BUY
$8.47 - $18.93 $458,227 - $1.02 Million
54,100 New
54,100 $197 Million

Others Institutions Holding ANVS

About Annovis Bio, Inc.


  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $48.7M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.